Oral Mucositis Market Size Grows at a CAGR of 7.37%

Introduction

Straits Research released its highly anticipated report, “Oral Mucositis Market Size & Outlook, 2026-2034.” According to the study, the global market size is valued at USD 1.92 billion in 2025 and is projected to expand to USD 3.63 billion by 2034, registering a compound annual growth rate (CAGR) of 7.37%.

Market Dynamics

The global oral mucositis market is driven by the rising prevalence of cancer patients undergoing chemotherapy and radiotherapy, as these treatments frequently cause mucosal injury, leading to a growing demand for effective prevention and management solutions. Increasing adoption of advanced therapies such as growth factors, epithelial protective agents, and photobiomodulation therapy further accelerates market growth. However, the market faces restraints due to the high cost of treatment, limited availability of targeted therapeutic options, and a lack of standardized clinical guidelines for management. On the other hand, significant opportunities lie in the development of novel biologics, regenerative therapies, and patient-friendly topical formulations, alongside growing research collaborations aimed at reducing treatment toxicity and improving quality of life for oncology patients.

Market Highlights

• Treatment: Growth factor /epithelial protective agents segment dominated the market in 2025, with a revenue share of 36.50%.
• Cause: The radiotherapy segment is anticipated to register the fastest CAGR of 8.36%, during the forecast period.
• Distribution Channel: The hospital pharmacies dominated the market in 2025, with a revenue share of 85.60%.
• Regional Insights: North America dominates the market with a 40.17% share, driven by the high incidence of cancer patients undergoing chemotherapy and radiotherapy, strong healthcare infrastructure, and the early adoption of advanced mucositis management therapies such as growth factors, barrier gels, and photobiomodulation.

Competitive Players

1. Amgen Inc.
2. Mundipharma International Limited
3. Swedish Orphan Biovitrum AB
4. EUSA Pharma Inc.
5. Galera Therapeutics Inc.
6. Enzychem Lifesciences Corporation
7. Oragenics Inc.
8. Soligenix
9. Jaguar Health
10. Monopar Therapeutics Inc.
11. Aurora BioScience Pty Ltd
12. EpicentRx, Inc.
13. BrainCool
14. GlycoMira Therapeutics, Inc.
15. INNOVATION
16. Allander Biotechnologies
17. Solasia Pharma K.K. 
18. NeoMedLight
19. MuReva Phototherapy Inc.
20. MitoImmune Therapeutics Inc.
21. Others

Recent Developments

Segmentation

1. By Treatment (2026-2034)
   1. Growth Factor /Epithelial Protective Agents
   2. Barrier/Coating Gels and Rinses
   3. Topical Analgesics
   4. Cryotherapy
   5. Low-level Laser/Photobiomodulation Therapy (LLLT)
   6. Antimicrobials
2. By Cause (2026-2034)
   1. Chemotherapy
   2. Radiotherapy
3. By Distribution Channel (2026-2034)
   1. Hospital Pharmacies
   2. Retail Pharmacies
   3. Others